Core Viewpoint - China National Pharmaceutical Group's subsidiary, Beijing Tide Pharmaceutical Co., has received clinical trial approval from the NMPA for its first-in-class innovative drug TRD221, aimed at treating osteoarthritis [1][2] Group 1: Company Developments - TRD221 is a complex polysaccharide drug developed in collaboration with the Chinese Academy of Medical Sciences, showcasing good biocompatibility and safety [1] - The drug acts as a key protein regulator that inhibits the release of inflammatory factors from the complement system, thereby promoting cartilage repair and delaying disease progression [1] Group 2: Industry Context - Osteoarthritis (OA) is a degenerative disease affecting joint cartilage, with approximately 595 million patients globally in 2020, expected to rise to 642 million by 2050 [2] - The prevalence of primary OA among individuals over 40 in China has reached 46.3%, with an increasing trend due to an aging population [2] - Current OA treatments primarily focus on pain relief, with significant unmet clinical needs in delaying disease progression and improving joint function [2] - TRD221 has shown dual effects in animal models by alleviating pain symptoms and improving structural damage, indicating its potential as a new treatment option for OA [2]